Sumit Aggarwal
President & CEO
Claimed by owner Eloxx Pharmaceuticals
Former names:
Treatment of Rare Genetic Diseases
Public on NASDAQ Apr, 2018
Eloxx Pharmaceuticals
www.globenewswire.com
•
Sep 14, 2022
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
www.globenewswire.com
•
Jul 5, 2022
Eloxx Pharmaceuticals Announces Changes to Board of Directors
www.globenewswire.com
•
Mar 30, 2022
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome
www.globenewswire.com
•
Mar 29, 2022
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation
www.globenewswire.com
•
Apr 1, 2021
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
www.globenewswire.com
•
Aug 4, 2020
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis
www.globenewswire.com
•
Nov 7, 2019
Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019
globenewswire.com
•
Feb 14, 2019
Eloxx Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Friday, March 1, 2019
globenewswire.com
•
Feb 4, 2019
Eloxx Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference in New York City on Monday, February 11, 2019
www.globes.co.il
•
Apr 26, 2018
Eloxx Pharmaceuticals raises $50m on Nasdaq
www.calcalistech.com
•
Apr 26, 2018
Biotech Company Eloxx Wants to Raise $50 Million on Nasdaq
www.prnewswire.com
•
Aug 2, 2017
Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million
www.finsmes.com
•
Jun 26, 2017
Eloxx Pharmaceuticals Raises US$6M in Funding - FinSMEs
www.finsmes.com
•
Jun 8, 2017
Eloxx Pharmaceuticals Raises US$24m in Series C Funding - FinSMEs
www.marketwired.com
•
Jun 8, 2017
http://www.marketwired.com/press-release/eloxx-pharmacueticals-receives-a-us5-million-investment-from-quark-venture-gf-securities-2220964.htm
www.businesswire.com
•
Jun 2, 2017
Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction
www.prnewswire.com
•
Nov 21, 2013
Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing
About
Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases including cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, ataxia-telangiectasia, beta thalassemia, and Tay-Sachs Hurler syndrome.
The companys approach allows it to move rapidly from a target drug-discovery program to clinical drug candidates. Eloxx Pharmaceuticals is building a pipeline of molecules designed for an array of genetic diseases caused by nonsense mutations.
In June 2017, Eloxx Pharmaceuticals reverse-merged with Sevion Therapeutics Inc. This acquisition transitioned Eloxx from a private to a publicly traded company.
The companys approach allows it to move rapidly from a target drug-discovery program to clinical drug candidates. Eloxx Pharmaceuticals is building a pipeline of molecules designed for an array of genetic diseases caused by nonsense mutations.
In June 2017, Eloxx Pharmaceuticals reverse-merged with Sevion Therapeutics Inc. This acquisition transitioned Eloxx from a private to a publicly traded company.
Primary Sector
Life Sciences & HealthTech
Products
ELX-02
Geographic markets
North America
Funding
Total Funding
$96.5M
Market Cap
$15.08M
Last Funding
$50M
Funding Stage
Total Rounds
3
Investors
10
News
(17)
www.globenewswire.com
•
Sep 14, 2022
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
www.globenewswire.com
•
Jul 5, 2022
Eloxx Pharmaceuticals Announces Changes to Board of Directors
www.globenewswire.com
•
Mar 30, 2022
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome
www.globenewswire.com
•
Mar 29, 2022
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation
www.globenewswire.com
•
Apr 1, 2021
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
www.globenewswire.com
•
Aug 4, 2020
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis
www.globenewswire.com
•
Nov 7, 2019
Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019
globenewswire.com
•
Feb 14, 2019
Eloxx Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Friday, March 1, 2019
globenewswire.com
•
Feb 4, 2019
Eloxx Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference in New York City on Monday, February 11, 2019
www.globes.co.il
•
Apr 26, 2018
Eloxx Pharmaceuticals raises $50m on Nasdaq
www.calcalistech.com
•
Apr 26, 2018
Biotech Company Eloxx Wants to Raise $50 Million on Nasdaq
www.prnewswire.com
•
Aug 2, 2017
Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million
www.finsmes.com
•
Jun 26, 2017
Eloxx Pharmaceuticals Raises US$6M in Funding - FinSMEs
www.finsmes.com
•
Jun 8, 2017
Eloxx Pharmaceuticals Raises US$24m in Series C Funding - FinSMEs
www.marketwired.com
•
Jun 8, 2017
http://www.marketwired.com/press-release/eloxx-pharmacueticals-receives-a-us5-million-investment-from-quark-venture-gf-securities-2220964.htm
www.businesswire.com
•
Jun 2, 2017
Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction
www.prnewswire.com
•
Nov 21, 2013
Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing
The Team
(2)
SA
LH
Lior Horonchik
Head Of Clinical Operations
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
$50M
Apr 2018
Stock Exchange
NASDAQ
Valuation
Undisclosed
$50M
Private Equity Funding
A Round
$8.5M
Nov 2013
1 Investors
$8.5M
C Round
$38M
Aug 2017
10 Investors
$38M
Mergers and Acquisitions
M&A
$7.6M
Apr 2021
Type
Acquisition
Acquired
Zikani Therapeutics
$7.6M
Others
Academic Techonology
Sep 2013
undefined
Molecular pipeline designed for an array of nonsense genetic diseases
Media gallery
(2)
Locations
Israel
Ness Ziona, Israel
Offices Abroad
480 Arsenal Wy, Watertown, MA 02472, USA
Locations
Israel
Ness Ziona, Israel
Offices Abroad
480 Arsenal Wy, Watertown, MA 02472, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,